Affordable Access

deepdyve-link deepdyve-link
Publisher Website

GRNOPC1: the world's first embryonic stem cell-derived therapy. Interview with Jane Lebkowski.

Authors
Type
Published Article
Journal
Regenerative medicine
Publication Date
Volume
6
Issue
6 Suppl
Pages
11–13
Identifiers
DOI: 10.2217/rme.11.77
PMID: 21999256
Source
Medline
License
Unknown

Abstract

Geron's Chief Scientific Officer, Jane Lebkowski, discusses the long road to clinical trials and the next steps for GRNOPC1. The long-awaited clinical trial of Geron's GRNOPC1 therapy for spinal cord injury has been one of the biggest stories in regenerative medicine over the past few years. The trial initially received the go-ahead from the US FDA in early 2009, but was put on clinical hold soon afterwards when an increased frequency of cysts was found in an animal experiment. Revision in release criteria and additional prospective animal studies allayed these concerns and the clinical hold was finally lifted in June 2010. The Phase I clinical trial enrolled its first patient in October 2010. As the world's first human trial of an embryonic stem cell-derived therapy, the trial has generated a huge amount of attention.

Statistics

Seen <100 times